A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis.

BMC Cancer · 2020 · PMC7364473 · PMID 32677982

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

marginal significancep = 0.051so close (0.05 < p ≤ 0.1)

The mean score of the appetite loss scale in the TOR group was slightly higher than that in the TAM group, with marginal significance (14.73 vs 5.56, p = 0.051), at the 6th month of follow-up.

also in 5,069 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.